Study Details
Testing study drug ABBV-142, for people with Idiopathic Pulmonary Fibrosis
(IRB#: IRB_00197853)
This research study is testing a drug called ABBV-142 to see if it can help people with Idiopathic Pulmonary Fibrosis (IPF), a lung disease. If you are able to join the study, you will take part for about 52 weeks (1 year), and you may choose to stay in the study for up to 28 months total. After the first 52 weeks, you can continue in the study and either keep taking the study drug or start taking it if you were previously given a placebo (a treatment with no active drug). During the study, you may need to visit the study center up to 30 times, depending on how long you stay in the study. To be eligible, you must be 40 years of age or older and have been diagnosed with IPF within the past 7 years before the screening visit.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Adults 40 years or older
- Diagnosed with IPF within the past 7 years before the screening visit
Exclusion Criteria
- A significant disease or condition other than IPF
- History of clinically significant drug or alcohol abuse within the last 6 months.
- History of stroke within 6 months prior to screening.
- Pregnancy
Will I be paid for my time?
Yes
IRB#: IRB_00197853
PI: Cheryl Pirozzi
Department: PULMONARY
Approval Date: 2026-08-05 06:00:00
Specialties: Pulmonary
I am Interested